{"id":"W4387808158","doi":"10.1016/j.annonc.2023.09.731","title":"1198P Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Adverse effect; Neuroendocrine tumors; Internal medicine; Nuclear medicine; Toxicity; Phases of clinical research; Gastroenterology; Radionuclide therapy; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009329755,0.001202482,0.001545832,0.000393561,0.0003276608,0.001121618,0.0007688646,0.001107725,0.008794467],"category_scores_gemma":[0.0006730564,0.0003235466,0.001321962,0.0003828583,0.0007304978,0.0007371142,0.0003613626,0.004265874,0.002468067],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008894094,"about_ca_system_score_gemma":0.001203655,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001064604,"about_ca_topic_score_gemma":0.002925115,"domain_scores_codex":[0.9997817,0.00008005508,0.000008796269,0.00003492062,0.00003105738,0.00006339525],"domain_scores_gemma":[0.9996017,0.00006914692,0.00006120525,0.00003313576,0.00002770889,0.000207059],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5415295,0.03018349,0.005828048,0.001402239,0.00244341,0.0006094502,0.0002320292,0.003930812,0.08441515,0.001752956,0.03664662,0.2910262],"study_design_scores_gemma":[0.6916034,0.2641794,0.01308202,0.0001010516,0.0009472024,0.0008154251,0.00008856578,0.002199933,0.009659764,0.0009560987,0.0163155,0.00005168647],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9595031,0.005974513,0.001735649,0.003313281,0.0006243887,0.002805742,0.009849449,0.000514054,0.01567977],"genre_scores_gemma":[0.9461722,0.005258563,0.004611155,0.003612961,0.000429395,0.002556925,0.0218496,0.0002512589,0.01525794],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008794467,"threshold_uncertainty_score":0.02942038,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08680295144206697,"score_gpt":0.4498335621748774,"score_spread":0.3630306107328105,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}